Problem: Diabetes (DM) increases cardiovascular (CV) and all-cause mortality despite aggressive risk factor modification. Our long term goal is to define novel targets for cardiovascular risk reduction in diabetes. Vascular mitochondria are a potential new target. Mitochondria regulate endothelial function and smooth muscle cell (SMC) proliferation and mitochondrial dysfunction is a hallmark of diabetes. Exercise elicits an adaptive improvement in mitochondrial quality in healthy vessels; this response is absent in diabetes. The question addressed in this proposal is whether pharmacological targeting of eNOS and SIRT with glucagon- like peptide 1 (GLP-1) can restore signaling to mitochondrial biogenesis and improve mitochondrial dynamics and vascular function. GLP-1 is a diabetes medication that also induces eNOS, SIRT1, mitochondrial biogenesis and autophagy 21. New preliminary data suggest that saxagliptin (SAXA), a dipeptidyl peptidase-4 inhibitor that increases circulating endogenous GLP-1, restores induction of eNOS and mitochondrial protein expression with exercise in DM and improves running distance. Hypotheses: Abnormal mitochondrial function and impaired stress mediated mitochondrial dynamics in the diabetic vasculature will be improved by GLP-1 via eNOS and SIRT1 signaling. SA #1: What is the impact of GLP-1 on vascular mitochondrial adaptation in DM? Rationale: Control rats subjected to 8 day exercise show increased activation of the mitochondrial biogenesis, improved mitochondrial function plus increased fusion and decreased fission. We will examine the impact of GLP-1 on vascular mitochondrial function and turnover in diabetes and use targeted deletion of eNOS, endothelial cell (EC) SIRT1, SMC SIRT1 with or without exercise to test mitochondrial homeostatic adaptation in vivo. Hypothesis 1.1: Intervention with GLP-1 will improve mitochondrial function through augmentation of vascular mitochondrial adaptation (biogenesis, fusion and autophagy) to exercise in high fat induced diabetes. Hypothesis 1.2: eNOS and/or SIRT1 are required for GLP-1 rescue of mitochondrial adaptation. Approach: 1a. Male C57BL6 on chow versus high fat (HF) diet for 10 weeks will be randomized to GLP-1 or vehicle with or without exercise for 8 days. 1b. c57eNOS -/- and c57b eNOS +/+ will be treated as in SA1a. 1c. c57 mice with EC or SMC deletion of SIRT1 and controls will be treated as in SA1a. These experiments will clarify the importance of eNOS and SIRT1 for vascular mitochondrial adaptation to exercise in vivo and define the impact of diabetes and GLP-1 on these pathways. SA #2: How does diabetes affect dynamic mitochondrial adaptation in vascular cells in vitro? Rationale: Regulation of mitochondrial function requires a complex interplay between mitochondrial biogene- sis and remodeling through fission, fusion and autophagy. Hypothesis 2.1: Endothelial cells and/or smooth muscle cells from DM models will have impaired mitochondrial dynamics. Hypothesis 2.2: GLP-1 will improve mitochondrial function and dynamics in DM cells through eNOS and/or SIRT. Approach: These experiments will examine the impact of DM and GLP-1 on mitochondrial quality and dynamics in vitro and employ genetic approaches to define the relative contribution of eNOS and SIRT for mitochondrial quality in vascular cells. Impact on the Veteran Population: Mitochondrial dynamics are a novel target to decrease excess CV risk in diabetes. Interventions targeting mitochondrial ROS have been consistently ineffective in human studies. Our observation that 8 days of treatment with SAXA restores vascular induction of mitochondrial biogenesis provides proof of concept that impaired vascular mitochondrial adaptation is targetable with a currently available drug. Pharmacological restoration of mitochondrial dynamics in diabetes could have implications for macrovascular and microvascular complications of diabetes.

Public Health Relevance

Vascular mitochondria are a potential new target for CVD risk reduction in diabetes. We recently reported that vascular stimulation of mitochondrial by exercise is absent in DM. Hypotheses: Abnormal mitochondrial function and impaired stress mediated mitochondrial dynamics in the diabetic vasculature will be improved by GLP-1 via eNOS and SIRT1 signaling. SA #1: What is the impact of GLP-1 on vascular mitochondrial adaptation in DM? These experiments will clarify the importance of eNOS and SIRT1 for vascular mitochondrial adaptation to exercise in vivo and define the impact of diabetes and GLP-1 on these pathways. SA #2: How does diabetes affect dynamic mitochondrial adaptation in vascular cells in vitro? These experiments will examine the impact of DM and GLP-1 on mitochondrial quality and dynamics in vitro. Impact on the Veteran Population: Restoration of mitochondrial homeostasis may impact CV fitness and thereby mortality. These studies may inform new therapeutic strategies for CVD reduction in diabetes.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX002046-04
Application #
9275386
Study Section
Cardiovascular Studies A (CARA)
Project Start
2013-10-01
Project End
2017-09-30
Budget Start
2016-10-01
Budget End
2017-09-30
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
VA Eastern Colorado Health Care System
Department
Type
Independent Hospitals
DUNS #
003252830
City
Denver
State
CO
Country
United States
Zip Code
80220
Cree-Green, Melanie; Scalzo, Rebecca L; Harrall, Kylie et al. (2018) Supplemental Oxygen Improves In Vivo Mitochondrial Oxidative Phosphorylation Flux in Sedentary Obese Adults With Type 2 Diabetes. Diabetes 67:1369-1379
Wahl, Matthew P; Scalzo, Rebecca L; Regensteiner, Judith G et al. (2018) Mechanisms of Aerobic Exercise Impairment in Diabetes: A Narrative Review. Front Endocrinol (Lausanne) 9:181
Tyagi, Alpna; Nguyen, Christy U; Chong, Thomas et al. (2018) SIRT3 deficiency-induced mitochondrial dysfunction and inflammasome formation in the brain. Sci Rep 8:17547
Chosich, Justin; Bradford, Andrew P; Allshouse, Amanda A et al. (2017) Acute recapitulation of the hyperinsulinemia and hyperlipidemia characteristic of metabolic syndrome suppresses gonadotropins. Obesity (Silver Spring) 25:553-560
Reusch, Jane E B; Manson, JoAnn E (2017) Management of Type 2 Diabetes in 2017: Getting to Goal. JAMA 317:1015-1016
McClatchey, Penn M; Frisbee, Jefferson C; Reusch, Jane E B (2017) A conceptual framework for predicting and addressing the consequences of disease-related microvascular dysfunction. Microcirculation 24:
Mason McClatchey, P; Bauer, Timothy A; Regensteiner, Judith G et al. (2017) Dissociation of local and global skeletal muscle oxygen transport metrics in type 2 diabetes. J Diabetes Complications 31:1311-1317
Mason McClatchey, P; Wu, Fan; Olfert, I Mark et al. (2017) Impaired Tissue Oxygenation in Metabolic Syndrome Requires Increased Microvascular Perfusion Heterogeneity. J Cardiovasc Transl Res 10:69-81
Keller, Amy C; Knaub, Leslie A; McClatchey, P Mason et al. (2016) Differential Mitochondrial Adaptation in Primary Vascular Smooth Muscle Cells from a Diabetic Rat Model. Oxid Med Cell Longev 2016:8524267
McClatchey, P Mason; Keller, Amy C; Bouchard, Ron et al. (2016) Fully automated software for quantitative measurements of mitochondrial morphology. Mitochondrion 26:58-71

Showing the most recent 10 out of 14 publications